These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25833701)

  • 1. Predictive markers of chemoradiotherapy for rectal cancer: comparison of biopsy specimens taken before and about 1 week after the start of chemoradiotherapy.
    Suzuki T; Sadahiro S; Tanaka A; Okada K; Saito G; Kamijo A; Akiba T; Kawada S
    Int J Clin Oncol; 2015 Dec; 20(6):1130-9. PubMed ID: 25833701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biopsy specimens obtained 7 days after starting chemoradiotherapy (CRT) provide reliable predictors of response to CRT for rectal cancer.
    Suzuki T; Sadahiro S; Tanaka A; Okada K; Kamata H; Kamijo A; Murayama C; Akiba T; Kawada S
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1232-8. PubMed ID: 23158058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker-Based Scoring System for Prediction of Tumor Response After Preoperative Chemoradiotherapy in Rectal Cancer by Reverse Transcriptase Polymerase Chain Reaction Analysis.
    Hur H; Tulina I; Cho MS; Min BS; Koom WS; Lim JS; Ahn JB; Kim NK
    Dis Colon Rectum; 2016 Dec; 59(12):1174-1182. PubMed ID: 27824703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive factors of tumor shrinkage and histological regression in patients who received preoperative radiotherapy for rectal cancer.
    Suzuki T; Sadahiro S; Fukasawa M; Ishikawa K; Kamijo A; Yasuda S; Makuuchi H; Ohizumi Y; Murayama C
    Jpn J Clin Oncol; 2004 Dec; 34(12):740-6. PubMed ID: 15640505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical analysis of tumour regression grade for rectal cancer after neoadjuvant chemoradiotherapy.
    García VM; Batlle JF; Casado E; Burgos E; de Castro J; Belda C; Barriuso J; Sánchez JJ; García-Cabezas MÁ; González-Barón M; Cejas P
    Colorectal Dis; 2011 Sep; 13(9):989-98. PubMed ID: 20718834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of immunohistochemical expression of p53, p21, p27, cyclin D1, and Ki67 in oral and oropharyngeal squamous cell carcinoma.
    Perisanidis C; Perisanidis B; Wrba F; Brandstetter A; El Gazzar S; Papadogeorgakis N; Seemann R; Ewers R; Kyzas PA; Filipits M
    J Oral Pathol Med; 2012 Jan; 41(1):40-6. PubMed ID: 21883486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy.
    Terzi C; Canda AE; Sagol O; Atila K; Sonmez D; Fuzun M; Gorken IB; Oztop I; Obuz F
    Int J Colorectal Dis; 2008 Jan; 23(1):37-45. PubMed ID: 17805549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
    Bertolini F; Bengala C; Losi L; Pagano M; Iachetta F; Dealis C; Jovic G; Depenni R; Zironi S; Falchi AM; Luppi G; Conte PF
    Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1455-61. PubMed ID: 17445998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-Infiltrating Lymphocytes in Biopsy Specimens Obtained 7 Days after Starting Chemoradiotherapy for Rectal Cancer Are Predictors of the Response to Chemoradiotherapy.
    Miyakita H; Sadahiro S; Suzuki T; Chan LF; Ogimi T; Okada K; Yamamoto S; Kajiwara H
    Oncology; 2020; 98(12):869-875. PubMed ID: 32799200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation.
    Lin CY; Tian YF; Wu LC; Chen LT; Lin LC; Hsing CH; Lee SW; Sheu MJ; Lee HH; Wang YH; Shiue YL; Wu WR; Huang HY; Hsu HP; Li CF; Chen SH
    J Clin Pathol; 2012 Aug; 65(8):687-92. PubMed ID: 22569540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic markers predictive of response to induction chemoradiotherapy for locally advanced rectal cancers.
    Kudrimoti M; Lee EY; Kang Y; Ahmed M; Mohiuddin M
    J Ky Med Assoc; 2007 Jan; 105(1):18-22. PubMed ID: 17310874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and clinical significance of cellular and acellular mucin in patients with locally advanced mucinous rectal cancer who underwent preoperative chemoradiotherapy followed by radical surgery.
    Kang CM; Lim SB; Hong SM; Yu CS; Hong YS; Kim TW; Park JH; Kim JH; Kim JC
    Colorectal Dis; 2016 Jan; 18(1):O10-6. PubMed ID: 26530997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the combination of molecular prognostic factors in tumor radiosensitivity in rectal cancer.
    Komuro Y; Watanabe T; Tsurita G; Muto T; Nagawa H
    Hepatogastroenterology; 2005; 52(63):666-71. PubMed ID: 15966178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
    Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
    Int J Clin Oncol; 2016 Oct; 21(5):946-952. PubMed ID: 26919982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term prognostic value of mesorectal grading after neoadjuvant chemoradiotherapy for rectal cancer.
    Madbouly KM; Hussein AM; Abdelzaher E
    Am J Surg; 2014 Sep; 208(3):332-41. PubMed ID: 24581995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistological expression of HIF-1α, GLUT-1, Bcl-2 and Ki-67 in consecutive biopsies during chemoradiotherapy in patients with rectal cancer.
    Havelund BM; Sørensen FB; Pløen J; Lindebjerg J; Spindler KL; Jakobsen A
    APMIS; 2013 Feb; 121(2):127-38. PubMed ID: 23030583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ki-67 and Survivin as Predictive Factors for Rectal Cancer Treated with Preoperative Chemoradiotherapy.
    Yoshikawa K; Shimada M; Higashijima J; Nakao T; Nishi M; Takasu C; Kashihara H; Eto S; Bando Y
    Anticancer Res; 2018 Mar; 38(3):1735-1739. PubMed ID: 29491110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different Impacts of Preoperative Radiotherapy and Chemoradiotherapy on Oncological Outcomes in Patients with Stages II and III Lower Rectal Cancer: A Propensity Score Analysis.
    Takiyama H; Kawai K; Ishihara S; Yasuda K; Otani K; Nishikawa T; Tanaka T; Kiyomatsu T; Hata K; Nozawa H; Morikawa T; Watanabe T
    Dig Surg; 2018; 35(3):212-219. PubMed ID: 28637039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncologic Outcome of ypT1-2N0 Rectal Cancer After Neoadjuvant Chemoradiotherapy Compared With pT1-2N0 Rectal Cancer.
    Yeop Oh S; Bae Kim Y; Wook Suh K
    Am J Clin Oncol; 2017 Oct; 40(5):512-516. PubMed ID: 26083556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma.
    Edden Y; Wexner SD; Berho M
    Colorectal Dis; 2012 May; 14(5):555-61. PubMed ID: 21689364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.